

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date: 28.05.2019

To

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Audited Financial Results For the Half Year and Financial Year ended 31st March, 2019

Dear Sir/ Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith:

1. Audited Financial Results of the Company for the half year and financial year ended March 31, 2019 as approved in the Board of Directors Meeting held today, along with the Auditor's Report thereon received from M/s Ajay K. Khanna & Co., Statutory Auditors of the Company.
2. Declaration pursuant to Reg. 33(3)(d) of Listing Regulations.

Kindly take this information on your record.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**

Rajesh Gupta
(DIN: 01423407)
Managing Director



Factory:
Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

AUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH, 2019

(In Lacs)

Particulars	Half Year Ended			For the year ended	Previous Year Ended
	31.03.2019	30.09.2018	31.03.2018	31.03.2019	31.03.2018
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	6736.31	5433.67	4684.98	12169.98	7604.47
II. Other income	14.94	8.33	62.82	23.27	68.72
III. Total Revenue (I + II)	6751.25	5442.00	4747.81	12193.25	7673.20
IV. Expenses:					
(a) Cost of materials consumed	4840.53	4048.12	3086.53	8888.65	5321.13
(b) Changes in Inventories	-93.89	-10.66	250.70	-104.55	-31.74
(c) Employee benefits expense	323.44	315.69	290.74	639.13	564.45
(d) Finance costs	132.76	101.51	82.31	234.27	158.06
(e) Depreciation and amortization expense	56.88	55.49	63.74	112.37	119.15
(f) Other expenses	1017.99	594.52	611.08	1612.51	1046.84
Total expenses	6277.71	5104.67	4385.10	11382.38	7177.88
V. Profit before exceptional and extraordinary items and tax (III-IV)	473.54	337.33	362.71	810.87	495.31
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit before extraordinary items and tax (V - VI)	473.54	337.33	362.71	810.87	495.31
VIII. Extraordinary Items	0.00	0.00	0.00	0.00	0.00
IX. Profit before tax (VII- VIII)	473.54	337.33	362.71	810.87	495.31
X Tax expense:					
(1) Current tax	170.12	66.41	75.64	236.53	103.49
(2) Deferred tax	2.74	0.00	19.41	2.74	19.41
(3) Mat Credit Entitlement	6.70	0.00	0.00	6.70	0.00
XI Profit (Loss) for the period from continuing operations (VII-VIII)	293.98	270.92	267.66	564.90	372.41
XII Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00



XV	Profit (Loss) for the period (XI + XIV)	293.98	270.92	267.66	564.90	372.41
XVI	Earnings per equity share:					
	(a) Basic & Diluted (Rs.)	5.67	5.23	5.16	10.90	7.18
	(b) Diluted (Rs.)	5.67	5.23	5.16	10.90	7.18

Notes :

1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on May 28, 2019.

2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule7 of the Companies (Accounts) Rules 2014 are not applicable.

3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.

4) The Figures for the half year ended 31st March 2019 and corresponding half year i.e. half year ended 31.03.2018 are the balancing figures between the audited figures in respect of the full financial year.

5)As per MCA Notification dated 16.02.2015, Companies whose shares are listed on SME exchange as referred in ChapterXB of SEBI(Issue of Capital Disclosure requirements) regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.

6) There were no Investors complaints pending as on 31.03.2019.

For ANG Life Sciences India Limited



(Managing Director)

Rajesh Gupta

(DIN : 01423407)

Date : 28.05.2019

Place : Amritsar

ANG Life Sciences India Ltd.
CIN : L24230PB2006PLC030341
Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar
Email ID : cs@anglifesciences.com
Website : www.anglifesciences.com


STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the year ended 31.03.2019	For the year ended 31.03.2018
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) <u>Share capital</u>	518.33	518.33
	(b) <u>Reserves and surplus</u>	2358.40	1798.50
	Sub-total-Shareholders' Fund	2876.73	2316.83
2	Non-current liabilities		
	(a) <u>Long-term borrowings</u>	627.76	768.33
	(b) <u>Other Long-term liabilities</u>	290.08	149.82
	(c) <u>Deferred Tax Liabilities (Net)</u>	39.69	36.95
	(d) <u>Long-term Provisions</u>	15.06	0.00
	Sub-total-non Current Liabilities	972.60	955.10
3	Current liabilities		
	(a) <u>Short Term Borrowings</u>	1241.45	639.89
	(b) <u>Trade Payables</u>	2181.46	2231.52
	(c) <u>Other current liabilities</u>	592.45	568.86
	(d) <u>Short-term provisions</u>	225.08	104.31
	Sub-total-Current Liabilities	4240.44	3544.60
	TOTAL EQUITY AND LIABILITIES	8089.76	6816.53
II.	ASSETS		
	Non-current assets		
1	(a) <u>Property, Plant and Equipment</u>		
	(i) <u>Tangible assets</u>	2075.94	2104.13
	(b) <u>Deferred Tax Assets (Net)</u>	0.00	0.00
	(c) <u>Other non-current assets</u>	15.92	22.93
	(d) <u>Other non-current Investments</u>	2.00	2.00
	Sub-total-non Current Assets	2093.86	2129.06
2	Current assets		
	(a) <u>Inventories</u>	653.73	774.29
	(b) <u>Trade receivables</u>	4174.87	3215.02
	(c) <u>Cash and cash equivalents</u>	437.15	147.94
	(d) <u>Short-term loans and advances</u>	730.15	550.21
	Sub-total-Current Assets	5995.90	4687.46
	TOTAL ASSETS	8089.76	6816.53
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited

(Managing Director)
Rajesh Gupta
(DIN : 01423407)





Auditor's Report on Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
ANG Lifesciences India Limited

We have audited the accompanying financial results of ANG Lifesciences India Limited for the Half Year ended March, 2019 and the year to date results for the period 01.04.2018 to 31.03.2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These Half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these half yearly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the half year ended 31st March, 2019 as well as the year to date results for the period from 01.04.2018 to 31.03.2019.

For Ajay K Khanna & Co.

Chartered Accountants

(Bhupinder Singh)

Partner

M. No: 513899

FRN : 012303N



Date : 28-05-2019

Place: Amritsar